Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
NCT05751018Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Started Dec 2021; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05751018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751018.